Wednesday, February 10, 2010, 8:09am EST - Canadian Markets open in 1 hour and 21 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Exelixis, Inc. (EXEL)

 On Feb 9: 6.42 USD   0.00 (0.00%)  
MORE ON EXEL
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Exelixis, Inc. (NasdaqNM:EXEL) Delayed quote dataEdit
Last Trade: 6.42 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 6.42
Open: N/A
Bid: 5.99 x 200
Ask: 1,999.00 x 300
1y Target Est: 6.18
Day's Range: N/A - N/A
52wk Range: 4.09 - 8.00
Volume: 0
Avg Vol (3m): 949,464
Market Cap: 689.42M
P/E (ttm): N/A
EPS (ttm): -1.35
Div & Yield: N/A (N/A%)
Exelixis, Inc. (EXEL)
1d  5d  3m  6m  1y  2y  5y  max 
Free Annual Reports
 Add EXEL to Portfolio   Download Data

HEADLINES
• Exelixis Announces February 9 Webcast of Presentation at the 12th Annual BioCEO and Investor Conference
Business Wire (Thu, Feb 4)
• Glaxo Brings Home the Bacon
at Motley Fool (Thu, Feb 4)
• How to Make a Billion Bucks in Biotech
at Motley Fool (Thu, Jan 28)
• Fearful Stocks for Greedy Investors
at Motley Fool (Tue, Jan 26)
• EXELIXIS INC Files SEC form 8-K, Other Events
EDGAR Online (Fri, Jan 15)
• 3 Reasons to Sell Sequenom Today
at Motley Fool (Fri, Jan 15)
• Exelixis: Volatility Expected to Subside in 2010
at Seeking Alpha (Mon, Jan 11)
• EXELIXIS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligatio
EDGAR Online (Wed, Dec 23)
• Exelixis, Inc.: Warming Up or Cooling Off?
at Motley Fool (Tue, Dec 22)
• Goodman named to Texas drug company board
at bizjournals.com (Tue, Dec 15)
• EXELIXIS INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Fri, Dec 11)
More Headlines for EXEL...
ANALYST
EPS Est (next year) (Dec-09) : -1.23
EPS Est (in 2 years) (Dec-10) : -1.08
Avg Rec (current)*: 2.4
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Exelixis, Inc. discovers and develops small molecule drugs for the treatment of cancer, and various metabolic and cardiovascular disorders. The company’s compounds primarily target multiple receptor tyrosine kinases simultaneously.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices